Ultragenyx Faces Class Action Over Alleged Misleading Statements About Setrusumab Efficacy
- Ultragenyx faces a class action lawsuit for allegedly misleading investors about its drug setrusumab's efficacy and associated risks.
- The lawsuit claims false statements inflated Ultragenyx's stock price, leading to financial losses after disappointing study results were disclosed.
- Multiple law firms are encouraging affected investors to participate in the class action without upfront costs, enhancing legal representation.
Ultragenyx Faces Class Action Over Allegations of Misleading Statements Regarding Setrusumab
A class action lawsuit has been initiated against Ultragenyx Pharmaceutical Inc. by Levi & Korsinsky, LLP, alongside other law firms, asserting that the biotechnology company may have misled investors regarding its investigational drug, setrusumab, intended for the treatment of Osteogenesis Imperfecta (OI). The lawsuit encompasses investors who bought Ultragenyx stock between August 3, 2023, and December 26, 2025, alleging that the company and its top executives provided false or misleading information pertaining to the efficacy of setrusumab while obscuring associated risks from a critical Phase III Orbit study. This class action seeks to pursue recovery for financial losses incurred when the study's disappointing results were disclosed, leading to a significant drop in Ultragenyx’s stock price.
The plaintiffs leverage the fraud-on-the-market doctrine established by the Supreme Court, which allows for the presumption that investors rely on the integrity of market information in an efficient market. This legal premise asserts that misleading statements can artificially inflate stock prices, thus impacting investors who may not have had direct contact with the disinformation. The lawsuit emphasizes that the alleged misleading proclamations by Ultragenyx, disseminated through regulatory filings and press releases, created a false sense of assurance in the drug’s potential, ultimately aligning a wide set of investors who may have encountered similar detrimental effects due to shared misinformation. The legal maneuvering reveals the challenges facing investors in reclaiming losses without the ability to prove individual reliance on misleading information.
As the litigation progresses, key legal questions emerge surrounding the materiality of the statements made by Ultragenyx and the impact these had on the stock price. The collective nature of the suit is portrayed as advantageous for affected investors who, without class action capabilities, would face considerable financial hurdles in addressing these claims individually. Joseph E. Levi, a partner at the law firm leading the charge, underscores the importance of such class actions in providing a framework for investors to seek justice and recovery from potential corporate wrongdoings. As deadlines for participation approach, the growing interest from affected investors signals a significant uptick in scrutiny regarding Ultragenyx's disclosures and operational transparency.
In parallel, other law firms, including Robbins Geller Rudman & Dowd LLP and Rosen Law Firm, are also calling on investors to join the ongoing litigation regarding Ultragenyx’s statements on the Phase III Orbit study. These firms emphasize that eligible investors could participate in the class action without incurring out-of-pocket costs under a contingency fee arrangement. Deadlines for filing motions to act as lead plaintiffs are set for April 6, 2026, prompting increased awareness among investors who may have experienced losses related to Ultragenyx's stock performance during the contested period. The escalation of these actions highlights the importance of legal representation for investors navigating the complexities of securities law in instances of perceived corporate misconduct.